Search results for "Sclerosis"

showing 10 items of 1583 documents

Impaired refractory periods of peripheral sensory nerves in multiple sclerosis.

1978

Maximum conduction velocity and relative refractory period (RRP) of median nerve sensory fibers were studied in 36 patients diagnosed as having multiple sclerosis (MS) and in 31 controls. Maximum conduction velocity did not differ in the two groups, but the RRP was significantly prolonged in MS patients. Increased RRP is observed mainly when peripheral nerve myelin is abnormal or damaged. Our findings support the assumption that peripheral nerve myelinated fibers are usually involved in MS.

Adultmedicine.medical_specialtyPathologyMultiple SclerosisRefractory Period Electrophysiologicalbusiness.industryRefractory periodMultiple sclerosisSensory systemmedicine.diseaseNerve conduction velocityMedian nerveSurgeryPeripheralMedian NerveMyelinmedicine.anatomical_structureNeurologyRefractorymedicineHumansNeurology (clinical)Neurons AfferentPeripheral NervesbusinessAnnals of neurology
researchProduct

Older age and markers of inflammation are strong predictors of clinical events in women with asymptomatic carotid lesions

2007

OBJECTIVE: Limited information exists regarding the association between markers of inflammation, such as high-sensitivity C-reactive protein (hs-CRP) and fibrinogen, and adverse events in postmenopausal women with subclinical atherosclerosis. Therefore, we investigated the prognostic impact of traditional risk factors and inflammation on adverse cardiac events in women with asymptomatic carotid lesions. DESIGN: We studied 250 postmenopausal women who were free of cardiovascular disease. Traditional cardiovascular risk factors were investigated, and laboratory analysis included measurement of plasma lipids, fibrinogen, and hs-CRP. The early phases of carotid atherosclerosis were assessed by …

Adultmedicine.medical_specialtyPathologySettore MED/09 - Medicina Internaclinical eventsMyocardial InfarctionmenopauseInflammationFibrinogenAsymptomaticcarotid atherosclerosiRisk FactorsInternal medicineOdds RatiomedicineHumansMyocardial infarctionAdverse effectStrokeAgedbiologybusiness.industryC-reactive proteinAge FactorsFibrinogenObstetrics and GynecologyOdds ratioMiddle AgedAtherosclerosismedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareStrokeC-Reactive ProteinCarotid Arteriesinflammationbiology.proteinFemaleRisk factormedicine.symptomTunica IntimaTunica MediabusinessBiomarkersFollow-Up Studiesmedicine.drugMenopause
researchProduct

Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

2020

IntroductionNatalizumab (NTZ) is one of the most effective treatment options for multiple sclerosis (MS) treatment. Our study aimed to evaluate the effectiveness of NTZ when administered according to the extended dosing strategy compared with standard 4-weekly administration in a large Italian MS population.Materials and methodsThis retrospective multicentre study included patients with relapsing-remitting MS (RR-MS) who received NTZ administrations between the 1 June 2012 and the 15 May 2018 and were followed by the ‘Italian MS Register’. All patients with MS were stratified into two groups based on NTZ administration schedule: standard interval dosing (SID) patients who received infusions…

Adultmedicine.medical_specialtyPopulationmultiple sclerosisDrug Administration Schedule03 medical and health sciencesMultiple Sclerosis Relapsing-Remittingnatalizumab0302 clinical medicineNatalizumabDosing schedulesInternal medicinemedicineHumansImmunologic Factorsnatalizumab risk stratification multiple sclerosis safety effectivenessDosingeducationProportional Hazards ModelsRetrospective Studies030304 developmental biology0303 health scienceseducation.field_of_studyProportional hazards modelbusiness.industryMultiple sclerosisRetrospective cohort studyMiddle Agedmedicine.diseasePsychiatry and Mental healthTreatment OutcomeItalyTolerabilitySettore MED/26 - NeurologiaSurgeryNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Stance control is not affected by paresis and reflex hyperexcitability: the case of spastic patients.

2001

OBJECTIVES Spastic patients were studied to understand whether stance unsteadiness is associated with changes in the control of voluntary force, muscle tone, or reflex excitability, rather than to abnormal posture connected to the motor deficit itself. METHODS Twenty four normal subjects, 12 patients affected by amyotrophic lateral sclerosis (ALS), seven by spastic paraparesis, and 14 by hemiparesis were studied. All patients featured various degrees of spasticity and paresis but were free from clinically evident sensory deficits. Body sway during quiet upright stance was assessed through a stabilometric platform under both eyes open (EO) and eyes closed (EC) conditions. The sudden rotation…

Adultmedicine.medical_specialtyPostureNeurological disorderMuscle tonePhysical medicine and rehabilitationReflexmedicineSpasticReaction TimeHumansSpasticityAmyotrophic lateral sclerosisParesisAgedAnalysis of VarianceElectromyographyFootMiddle Agedmedicine.diseaseParesisPsychiatry and Mental healthmedicine.anatomical_structureHemiparesisMuscle SpasticityPapersReflexPhysical therapySurgeryNeurology (clinical)medicine.symptomPsychologyJournal of neurology, neurosurgery, and psychiatry
researchProduct

How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome?

2007

Despite their young age, women with polycystic ovary syndrome (PCOS) have increased cardiovascular risk. Besides normal concentrations of low-density lipoprotein (LDL) cholesterol, dyslipidemia is very common and includes elevated triglyceride levels and low high-density lipoprotein cholesterol concentrations. Recent findings also showed that women with PCOS have qualitative LDL alterations, with increased levels of atherogenic small, dense LDL particles. Such lipid abnormalities constitute a common form of dyslipidemia, the so-called atherogenic lipoprotein phenotype (ALP), associated with a greater cardiovascular risk. Weight reduction and increased physical activity may constitute first-…

Adultmedicine.medical_specialtySettore MED/09 - Medicina Interna10265 Clinic for Endocrinology and Diabetology610 Medicine & healthRisk AssessmentSeverity of Illness IndexSettore MED/13 - Endocrinologiachemistry.chemical_compoundWeight lossInternal medicinemedicineHumansatherosclerosis high-density lipoprotein cholesterol polycystic ovary syndrome small and dense low-density lipoprotein triglyceridesDyslipidemiasTriglyceridebusiness.industryCholesterolCholesterol HDLnutritional and metabolic diseasesObstetrics and Gynecology2729 Obstetrics and GynecologyCholesterol LDLmedicine.diseaseAtherosclerosisPrognosisPolycystic ovaryMetforminEndocrinologyTreatment OutcomechemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Drug Therapy CombinationFemaleControlled Clinical Trials as Topicmedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessPioglitazoneDyslipidemiamedicine.drugLipoproteinPolycystic Ovary Syndrome
researchProduct

THE OPTIMIZATION OF INTERFERON FOR MS STUDY: 375 MICROG INTERFERON BETA-1B IN SUBOPTIMAL RESPONDERS.

2008

We aimed to evaluate the safety and MRI efficacy of interferon beta-1b (IFNbeta-1b) 375 microg (subcutaneously [sc] every other day [eod]) in relapsing-remitting multiple sclerosis (RRMS) patients with a suboptimal response to IFNbeta-1b 250 microg, i.e., with MRI activity or relapses. The OPTimization of Interferon for MS (OPTIMS) study was a prospective multicenter randomized phase 2 trial comprising a 6-month run-in phase (to identify suboptimal responders) and a 6-month randomized phase of open-label clinical and blinded MRI follow-up. During run-in all patients were treated with IFNbeta-1b 250 microg sc eod; during the study phase suboptimal treatment responders were randomized either …

Adultmedicine.medical_specialtyTime FactorsAdolescentInjections Subcutaneoussuboptimal treatment responseGastroenterologyDrug Administration Schedulelaw.inventionYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansSingle-Blind MethodProspective StudiesAdverse effectProspective cohort studyinterferon beta (IFNβ)immunomodulatory drugSubclinical infectionDose-Response Relationship Drugbusiness.industryInterferon beta-1bInterferon-betaMiddle AgedMagnetic Resonance ImagingConfidence intervalSurgeryClinical trialTreatment OutcomeNeurologyRelative riskmultiple sclerosiMRI activitySettore MED/26 - NeurologiaNeurology (clinical)businessFollow-Up StudiesInterferon beta-1b
researchProduct

Aortic root dilation in associated with the reduction in capillary density observed at nailfold capillaroscopy in SSc patients

2020

Systemic sclerosis (SSc) is an autoimmune disease characterized by endothelial dysfunction and fibroblasts activation. Microvascular disease may be easily observed by means of nailfold capillaroscopy. Recent evidences emphasized also the involvement of large-medium arteries in SSc, mainly in terms of increased stiffness of the vessel wall. The study aims to measure aortic root diameter in a cohort of SSc patients and to correlate echocardiographic findings with the capillaroscopic pictures. We analyzed the clinical records of 125 consecutive SSc patients (M/F 14/111, mean age 55 ± 12.7 years, median disease duration 11 years) referring in 3 second-level rheumatology centers. All subjects un…

Adultmedicine.medical_specialtyVasa vasorumMicroscopic Angioscopy03 medical and health sciences0302 clinical medicineRheumatologyInternal medicineMedicineAortic rootHumans030212 general & internal medicineEndothelial dysfunctionNailfold CapillaroscopyVideocapillaroscopyAged030203 arthritis & rheumatologyAutoimmune diseaseScleroderma Systemicintegumentary systembusiness.industryMicroangiopathyGeneral MedicineMiddle Agedmedicine.diseaseDilatationRheumatologyCapillariesmedicine.anatomical_structureCapillary densityNailsVasa vasorumCardiologySystemic sclerosisbusinessAortic root dilation
researchProduct

Hyaluronic acid and platelet-rich plasma, a new therapeutic alternative for scleroderma patients: a prospective open-label study

2019

Abstract Background Systemic sclerosis is a systemic connective tissue disease characterized by endothelium damage, fibrosis, and subsequent atrophy of the skin. Perioral fibrosis produces a characteristic microstomia together with microcheilia, both of which cause severe difficulties and affects patients’ daily life, such as eating and oral hygiene. Since there are no effective and specific therapies, we have aimed at evaluating the response to filler injections of hyaluronic acid together with platelet-rich plasma. Methods Ten female patients aged between 18 and 70 were included in this study. Each patient was treated with three filler injections of hyaluronic acid and platelet-rich plasm…

Adultmedicine.medical_specialtylcsh:Diseases of the musculoskeletal systemHyaluronic acidMicrocheiliaGastroenterologySystemic sclerosi030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineAtrophyPlatelet-rich plasmaFibrosisInternal medicineHyaluronic acidmedicineHumansProspective StudiesHyaluronic acid; Platelet-rich plasma; Systemic sclerosis; TherapySkin030203 arthritis & rheumatologyScleroderma SystemicViscosupplementsMicrostomiabusiness.industryMiddle Agedmedicine.diseaseConnective tissue diseaseElasticityLipRheumatologySettore MED/16 - ReumatologiaTreatment OutcomechemistryPlatelet-rich plasmaQuality of LifeSystemic sclerosisFemaleTherapylcsh:RC925-935businessResearch ArticleArthritis Research & Therapy
researchProduct

Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames)

2017

Objective To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). Methods Patients with SSc‐related RP were randomized 1:1 to placebo (n = 38) or selexipag (n = 36) in individualized doses (maximum of 1,600 μg twice daily) during a 3‐week titration period. The primary end point was the weekly average number of RP attacks during the study maintenance period, analyzed using a Bayesian approach with a negative binomial model adjusted for baseline number of RP attacks. Other outcome measures included Raynaud's Condition Score (RCS), RP attack duration, and treat…

Adultmedicine.medical_specialtymedicine.drug_classImmunologyIschemiaSystemic SclerosisCalcium channel blockerScleroderma03 medical and health sciences0302 clinical medicineRheumatologyAcetamidesmedicineHumansImmunology and Allergy030212 general & internal medicineskin and connective tissue diseasesIntensive care medicine030203 arthritis & rheumatologyScleroderma Systemicintegumentary systembusiness.industryVascular diseaseRaynaud DiseaseVasospasmmedicine.diseaseSurgeryClinical trialPyrazinesPillOriginal ArticleSugarsbusinessVasodilating AgentArthritis & Rheumatology
researchProduct

Corticobulbar tract involvement in amyotrophic lateral sclerosis. A transcranial magnetic stimulation study

1998

We investigated corticobulbar tract function by recording from the tongue and orofacial muscles and using transcranial magnetic stimulation (TMS) in 30 patients with amyotrophic lateral sclerosis (ALS) in order to improve the diagnostic yield in the detection of subclinical upper motor neuron (UMN) dysfunction. A UMN lesion was assumed when the peripheral conduction time and amplitude of the M-wave were within normal range and either the response to cortical stimulation was absent, or the central conduction time was delayed (> mean + 2.5 SD). Only two patients showed clinical evidence of UMN involvement in the cranial nerves, while TMS demonstrated corticobulbar tract dysfunction in the oro…

Adultmedicine.medical_treatmentPyramidal TractsFacial MusclesCentral nervous system diseaseTongueTonguePhysical StimulationmedicineHumansAmyotrophic lateral sclerosisAgedSubclinical infectionMouthbusiness.industryUpper motor neuronAmyotrophic Lateral SclerosisCranial nervesAnatomyMiddle Agedmedicine.diseaseTranscranial Magnetic StimulationTranscranial magnetic stimulationmedicine.anatomical_structureCorticobulbar tractNeurology (clinical)businessBrain
researchProduct